New Stock News | Zhiyi Biotech Submits Listing Application to the Hong Kong Stock Exchange

According to the disclosure made by the Hong Kong Stock Exchange on June 18th, Guangzhou Ziyi Biotechnology Co., Ltd. (referred to as Ziyi Biotechnology) has submitted an application to the main board of the Hong Kong Stock Exchange, with Guotou Securities International and CISI FIN as its joint sponsors. The prospectus shows that Ziyi Biotechnology is a clinical-stage biopharmaceutical company, focusing on the field of living biological drugs (LBP), with businesses covering gastrointestinal diseases, tumors, tumor treatment-related complications, metabolic diseases, and autoimmune diseases. The company's core product SK08 and key product SK10 have achieved multiple research and development milestones.